3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
5
Lung Neoplasms
2
Rhabdoid Tumor
1
Papillary renal cell carcinoma, sporadic
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Melanoma
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Hereditary leiomyomatosis and renal cell cancer
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Choroid Plexus Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma
1
Breast Neoplasms
1
Interventions
Dexamethasone
3
Cyclophosphamide
3
Bortezomib
3
fludarabine phosphate
2
Melphalan
2
Etoposide
2
pomalidomide
1
pembrolizumab
1
isatuximab
1
fludarabine
1
elotuzumab
1
carfilzomib
1
belantamab mafodotin
1
Whole-Body Irradiation
1
Thalidomide
1
Tacrolimus
1
Sirolimus
1
Peripheral Blood Stem Cell Transplantation
1
Patient Reported Outcome Measures
1
Mycophenolic Acid
1
Methotrexate
1
Lenalidomide
1
Doxorubicin
1
Cyclosporine
1
Cisplatin
1
Calcium Dobesilate
1
Busulfan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neoplasms, Plasma Cell
×
Erlotinib Hydrochloride
×
30 days
×
Clear all
No trials found.